The Lancet publishes Lundbeck Vyepti study
The firm’s study of migraine treatment Vyepti has been published in the top-ranking medical journal, which is a stamp of approval for Lundbeck’s research quality, according to Head of R&D Johan Luthman.
by marketwire, translated by daniel pedersen
The Lancet, a top-ranking medical journal, has published results from pharmaceutical firm Lundbeck’s Deliver study of migraine drug Vyepeti, the firm announced in a press release on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
